Laurus Labs Posts 31% Revenue Growth and 33.2% EBITDA Margin in H1 FY27, Expands CDMO Platform with Two Acquisitions

For Q2 FY27, Laurus Labs recorded revenue of ₹2,206 crore, a 33% increase compared to the prior year quarter, with EBITDA rising 78% to ₹762 crore and gross margins expanding to 63%. The company's CDMO segment revenue grew 75% year over year, driven largely by small molecule manufacturing, while the Affordable Medicines segment increased revenue by 15%.

The firm inaugurated a commercial-scale peptide manufacturing facility in Vizag with over 16,000L solid-phase peptide synthesis capacity and is expanding capacity further to meet growing demand for peptide therapeutics. Additionally, large-scale API capacity construction in Vizag progressed well.

Laurus Labs entered definitive agreements to acquire 60% of Canada-based Galenvs Sciences, specialists in oligonucleotides and magnetic nanoparticles, and 52% of SI&C Resins, a peptide-resin technology company. These acquisitions aim to enhance Laurus's technology platforms and supply chain security, positioning it for growth in the oligonucleotide market.

The company declared an interim dividend of ₹1.00 per share and reported capital expenditure equal to 20% of revenue, reflecting ongoing investments in manufacturing capacity and technology. R&D investments totaled ₹183 crore for H1 FY27, supporting biologics and advanced drug development.

Quality audits numbered 59, all passed without critical findings. Laurus continued operational progress on sustainability goals, aligned with science-based targets for greenhouse gas reductions.